In antibody drug development, accurate identification of antibody light chains (Kappa and Lambda) is crucial for assessing drug affinity, stability, and conducting pharmacokinetic studies. As an important component of the antibody's variable region, the light chain directly affects the antibody's antigen-binding properties and structural integrity. However, traditional detection tools often suffer from cross-reactivity or background interference, leading to distorted light chain quantification results and hindering the accurate analysis of antibody drugs.
Leveraging its nanobody technology platform, AlpVHHs has once again broken through detection bottlenecks, launching its latest masterpiece—the Anti-Human Kappa, AlpSdAbs VHH and Anti-Human Lambda, AlpSdAbs VHH series. This product series accurately identifies the Kappa or Lambda light chains of Human IgG, exhibits no cross-reactivity, covers multiple detection platforms, and provides a brand-new solution for antibody drug development and quality control!
Fig. Schematic diagram of Human IgG structure and its recognizable domains
The Anti-Human Kappa series specifically binds to Kappa light chains of Human IgG, and the Anti-Human Lambda series specifically binds to Lambda light chains of Human IgG. These two types do not cross-react, ensuring the accuracy and specificity of the detection signal and truly reflecting the compositional characteristics of the antibody drug's light chains.
The absence of Fc fragments significantly reduces non-specific binding, improving detection clarity and accuracy.
Accurately detects low concentrations of light chain components, providing reliable data support for drug activity assessment, affinity determination, and pharmacokinetic studies, meeting the high standards required for antibody drug development.
Widely applicable to various experimental platforms such as ELISA, WB, Flow Cyt, ICC/IF, SPR, BLI, and IP, achieving precise quantitative detection and meeting the needs of different development stages and quality control processes.
(1) Validation data of different subtype antibodies
ELISA results showed that Anti-Human kappa, AlpSdAbs VHH(HRP) (Code: 023-102-005) exhibited high sensitivity binding and specific recognition for Human kappa subtypes 1/2/3/4.
(2) Specificity validation data
ELISA results showed that Anti-Human kappa, AlpSdAbs VHH(HRP) (Code: 023-102-005) specifically identified Human kappa fragments with clear identification location and high specificity.
(1) Validation data of different subtype antibodies
ELISA results showed that Anti-Human lambda, AlpSdAbs VHH(HRP) (Code: 023-103-005) exhibited high sensitivity binding and specific recognition for Human lambda subtypes 1/2/3/4.
(2) Specificity validation data
ELISA results showed that Anti-Human lambda, AlpSdAbs VHH(HRP) (Code: 023-103-005) specifically identified Human lambda fragments with clear location and high specificity.
Code | Description | Applications |
023-102-011 | Flow Cyt | |
023-102-010 | Flow Cyt | |
023-102-007 | WB,ELISA,ICC/IF,Flow Cyt | |
023-102-008 | WB,ELISA,ICC/IF,Flow Cyt | |
023-102-009 | WB,ELISA,ICC/IF,Flow Cyt | |
023-402-007 | WB,ELISA,ICC/IF,Flow Cyt | |
023-402-008 | WB,ELISA,ICC/IF,Flow Cyt | |
023-402-009 | WB,ELISA,ICC/IF,Flow Cyt | |
023-102-004 | WB,ELISA,IP,Purification,BLI,SPR | |
023-102-005 | WB,ELISA | |
023-402-001 | WB,ICC/IF,ELISA,IP,Flow Cyt | |
023-402-004 | WB,ELISA,IP | |
023-402-005 | WB,ELISA |
Code | Description | Applications |
023-103-011 | Flow Cyt | |
023-103-010 | Flow Cyt | |
023-103-007 | WB,ELISA,ICC/IF,Flow Cyt | |
023-103-008 | WB,ELISA,ICC/IF,Flow Cyt | |
023-103-009 | WB,ELISA,ICC/IF,Flow Cyt | |
023-103-005 | WB, ELISA | |
023-403-001 | WB,ICC/IF,ELISA,IP,Flow Cyt | |
023-403-004 | WB,ELISA,IP | |
023-403-005 | WB,ELISA | |
023-103-004 | WB,ELISA,IP.Purification,BLI,SPR |
